Dilip Shah
Mr Dilip G. Shah graduated from the premier business school in India, the Indian Institute of Management (IIM), Ahmedabad. He has 52 years (1966 onwards) of varied experience in the pharmaceutical industry.
Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance (www.ipa-india.org), Member of the Expert Review Committee of Access to Medicine (ATM) Index (www.atmindex.org); Member of the CPhI International Advisory Board; and Member of the Board of Advisors of Pharmabiz.com (Weekly). Mr Shah is an independent director on the Boards of Fresenius Kabi Oncology Ltd (www.fresenius-kabi-oncology.com), Anuh Pharma Ltd (www.anuhpharma.com), Shaily Engineering Plastics Ltd (www.shaily.com) and CEO of Vision Consulting Group (www.vision-india.com); a firm specialized in strategic planning.
Before starting Vision in 1997, he was a Member of the Board of Directors of Pfizer-India for whom he worked for 30 years. He was also Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms (2005-07) and (2010-11). He was a Member of the Official Indian Delegation to WTO Ministerial Conference at Cancun. He also appeared before the U.S. International Trade Commission (USITC) and testified in Investigation No.332-543 Hearing in Washington DC in 2014.
He has addressed several WTO workshops on TRIPS, WIPO seminars on IPRs and Public Health, WHO meetings on Access to Medicine besides several other international meetings and conferences.
Mr Dilip G. Shah graduated from the premier business school in India, the Indian Institute of Management (IIM), Ahmedabad. He has 52 years (1966 onwards) of varied experience in the pharmaceutical industry.
Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance (www.ipa-india.org), Member of the Expert Review Committee of Access to Medicine (ATM) Index (www.atmindex.org); Member of the CPhI International Advisory Board; and Member of the Board of Advisors of Pharmabiz.com (Weekly). Mr Shah is an independent director on the Boards of Fresenius Kabi Oncology Ltd (www.fresenius-kabi-oncology.com), Anuh Pharma Ltd (www.anuhpharma.com), Shaily Engineering Plastics Ltd (www.shaily.com) and CEO of Vision Consulting Group (www.vision-india.com); a firm specialized in strategic planning.
Before starting Vision in 1997, he was a Member of the Board of Directors of Pfizer-India for whom he worked for 30 years. He was also Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms (2005-07) and (2010-11). He was a Member of the Official Indian Delegation to WTO Ministerial Conference at Cancun. He also appeared before the U.S. International Trade Commission (USITC) and testified in Investigation No.332-543 Hearing in Washington DC in 2014.
He has addressed several WTO workshops on TRIPS, WIPO seminars on IPRs and Public Health, WHO meetings on Access to Medicine besides several other international meetings and conferences.
Articles: Dilip Shah
India’s Drug Regulatory Reforms: Building Trust
India / Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output and drug inspectors. Improving the image of drug inspectors- will require investments in “infrastructure”. The key elements of this “infrastructure”, besides more labs and…
Latest Report
